{"id":15357,"date":"2022-01-12T19:08:43","date_gmt":"2022-01-12T13:38:43","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=15357"},"modified":"2022-01-12T20:10:21","modified_gmt":"2022-01-12T14:40:21","slug":"antibody-drug-conjugate-pipeline","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/antibody-drug-conjugate-pipeline","title":{"rendered":"Insights into the Evolving Landscape of Antibody-Drug Conjugate (ADC) &#038; the Key Companies in the Segment"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69d1b62e989fd\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69d1b62e989fd\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/antibody-drug-conjugate-pipeline\/#Seagen_Inc\" >Seagen Inc.<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/antibody-drug-conjugate-pipeline\/#Daiichi_Sankyo\" >Daiichi Sankyo<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/antibody-drug-conjugate-pipeline\/#ADC_Therapeutics\" >ADC Therapeutics<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/antibody-drug-conjugate-pipeline\/#Roche\" >Roche<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/antibody-drug-conjugate-pipeline\/#Gilead_Sciences\" >Gilead Sciences<\/a><\/li><\/ul><\/nav><\/div>\n\n<p>In the year 2000, the first-ever Antibody-drug Conjugate (ADC) &#8211; <strong>Mylotarg<\/strong>, was launched by <strong>Pfizer <\/strong>and was considered a miracle in cancer treatment. And it appeared like there was no looking back for these antibody-drug conjugates. But it took almost another 11 years for the next ADC to launch in the market &#8211; <strong>Adectris <\/strong>by <strong>Seagen Inc. <\/strong>After twenty years of ongoing clinical trials of ADC research and development, it is now that this field constitutes almost 50 major pharmaceutical companies continuously working to develop a plethora of antibody-drug conjugates targeted to treat a wide range of tumor types. <\/p>\n\n\n\n<p>At present, there are 11 FDA-approved <a href=\"https:\/\/www.delveinsight.com\/report-store\/antibody-drug-conjugate-market\">antibody-drug conjugates in the oncology market<\/a>. ADCs are designed using many elements, including a monoclonal antibody targeting the cancer-antigen, a payload anti-cancer medicine (chemotherapy drug),\u00a0 a \u201clinker\u201d to cleave off payload into cancerous cells a conjugation technology that binds the payload and linker to the antibody. It is a challenging procedure to develop target antibody-drug conjugates, but scientists still have achieved it. It is a miraculous technology that is helping companies that are dealing with tough-to-treat cancers. <\/p>\n\n\n\n<p><strong>Following mentioned are some of the companies that are currently proactive in developing antibody-drug conjugates-<\/strong><\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Seagen_Inc\"><\/span><strong>Seagen Inc.<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Seagen Inc., an American biotechnology company that is considered one of the most prominent leaders of the antibody-drug conjugate field with one of the deepest ADC pipelines in the industry. Currently, they have 8 ADCs in the pipeline. Seagen grabbed two bladder cancer FDA approvals for its ADC product Padcev and is working towards establishing markets for <strong>Padcev <\/strong>and <strong>Adcetris. <\/strong>Both of these ADCs are designed for Hodgkin lymphoma treatment. Another ADC, namely <strong>tisotumab vedotin,<\/strong> was granted FDA approval for cervical cancer treatment on September 20, 2021.<\/p>\n\n\n\n<p>It has many additional <a href=\"https:\/\/www.delveinsight.com\/blog\/the-snippet-weaponized-antibodies-use-new-tricks-to-fight-cancer\">antibody-drug conjugate products<\/a> in the pipeline, including <strong>disitamab vedotin<\/strong>. It is a HER2-targeted ADC very recently licensed from China\u2019s RemeGen. Seagen already has another HER2-targeted drug in its portfolio, <strong>Tukysa<\/strong>, which was approved in April 2020, but the RemeGen deal brings it against potential rivalry to two of the highest-selling antibody-drug conjugates, AstraZeneca and <strong>Daiichi Sankyo\u2019s Enhertu and Roche\u2019s Kadcyla<\/strong>. The recent approval in <strong>tisotumab vedotin <\/strong>has also accelerated the cervical cancer market opportunities for Seagen. This drug is being tested in combination with many other drugs in the first-line treatment setting, including Keytruda. With other ADCs in the pipeline, Seagen is also anticipated to break into the triple-negative breast cancer market.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-daiichi-sankyo\"><span class=\"ez-toc-section\" id=\"Daiichi_Sankyo\"><\/span><strong>Daiichi Sankyo<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>In collaboration with AstraZeneca, Daiichi Sankyo\u2019s Enhertu was a blockbuster Antibody-drug Conjugate when it was launched in the market for metastatic HER2-positive breast cancer treatment. This drug also got FDA approval last January for HER2-positive stomach cancer in patients who previously got Herceptin. Daiichi Sankyo and AstraZeneca are testing Enhertu in various other cancers such as lung cancer, colorectal cancer, and other solid tumors. Daiichi Sankyo currently has 7 ADCs in the pipeline, including targets for B7-H3, GRP20, CDH6, and TA-MUC1.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"1024\" height=\"624\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/01\/12190238\/Number-of-ADCs-in-the-Pipeline-by-Key-Players-1024x624.jpg\" alt=\"ADC-in-Pipeline-by-key-companies\" class=\"wp-image-15360\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/01\/12190238\/Number-of-ADCs-in-the-Pipeline-by-Key-Players-1024x624.jpg 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/01\/12190238\/Number-of-ADCs-in-the-Pipeline-by-Key-Players-300x183.jpg 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/01\/12190238\/Number-of-ADCs-in-the-Pipeline-by-Key-Players-768x468.jpg 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/01\/12190238\/Number-of-ADCs-in-the-Pipeline-by-Key-Players.jpg 1500w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><figcaption><strong>Antibody-Drug Conjugate (ADC)<\/strong> <strong>in the Pipeline<\/strong><\/figcaption><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"ADC_Therapeutics\"><\/span><strong>ADC Therapeutics<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Last year\u2019s April was the month when Switzerland-based ADC Therapeutics got approval for its first Antibody-drug Conjugate product <strong>Zynlonta <\/strong>for relapsed or refractory <a href=\"https:\/\/www.delveinsight.com\/report-store\/diffuse-large-b-cell-lymphoma-market\">diffuse large B-cell lymphoma (DLBCL) treatment<\/a>. The company mainly focuses on ADC development; just as its name suggests, it has almost 6 ADC products lined up in the pipeline. <strong>Zynlonta <\/strong>is a CD19-targeted ADC that is considered competition for other <a href=\"https:\/\/www.delveinsight.com\/report-store\/cd-19-inhibitor-pipeline-insight\">CD19-targeted treatments<\/a> such as <strong>Novartis\u2019s CAR-T treatments, Gilead Sciences, and Bristol Myers Squibb.&nbsp;<\/strong><\/p>\n\n\n\n<p>ADC Therapeutics is also hoping to expand Zynlonta&#8217;s reach and is currently underway many clinical trials for several types of lymphoma treatment. The company\u2019s second ADC asset is <strong>camidanlumab tesirine (cami)<\/strong>, which is a CD25-targeted <a href=\"https:\/\/www.delveinsight.com\/report-store\/hodgkins-lymphoma-pipeline-insight\">drug for Hodgkin lymphoma<\/a>. In addition to that, the longer-term pipeline for the company constitutes ADCs targeting tumor antigens AXL, KAAG1, and DLK1.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Roche\"><\/span><strong>Roche<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Drug giant Roche\u2019s very first ADC, <strong>Kadcyla<\/strong>, was approved by FDA in 2013 for <a href=\"https:\/\/www.delveinsight.com\/report-store\/metastatic-her2-positive-breast-cancer-market\">HER2-positive metastatic breast cancer treatment<\/a> after previous treatment with Roche\u2019s own Herceptin and chemotherapy. It was developed in collaboration with Immunogen\u2019s ADC technology. The second Antibody-drug Conjugate owned by Roche was named <strong>Polivy, <\/strong>which was approved in 2019 by FDA. It was used alongside bendamustine and Roche\u2019s Rituxan for diffuse large B-cell lymphoma (DLBCL) treatment. Roche is hoping for a spectacular expansion of Polivy as it strives to fuel Kadcyla&#8217;s growth. <strong>AstraZeneca and Daiichi <\/strong>Sankyo&#8217;s competitor HER2 ADC, <strong>Enhertu<\/strong>, pose the greatest competitive challenge to <strong>Roche<\/strong>. Currently, Roche has 2 Antibody-drug Conjugate products in the pipeline.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Gilead_Sciences\"><\/span><strong>Gilead Sciences<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Gilead Sciences acquired Immunomedics in 2020, which also bagged it an Antibody-drug Conjugate in the pipeline of the latter &#8211; <strong>Trodelvy.<\/strong> In April 2020, FDA granted approval to Trodelvy for metastatic triple-negative breast cancer treatment. Breast cancer is the main target for Trodelvy, but it will face continuous competition from the triple-negative breast cancer market among antibody-drug conjugates. In addition to breast cancer, Trodelvy recently was given a green flag by the FDA for third-line metastatic bladder cancer treatment in addition to breast cancer. It is also being tested in multiple trials either by academics or pharmaceutical industries for <a href=\"https:\/\/www.delveinsight.com\/blog\/most-common-cancers-2\">different types of cancer<\/a>, including breast, non-small cell lung, bladder, head and neck, endometrial and ovarian cancers. Gilead Sciences has 1\u00a0 Antibody-drug Conjugate in the pipeline.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"1024\" height=\"542\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/01\/12190357\/Leading-Players-in-the-Antibody-Drug-Conjugate-ADC-Market-01-01-01-01-1024x542.jpg\" alt=\"key-companies-in-Antibody-Drug-Conjugate-ADC-Market\" class=\"wp-image-15361\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/01\/12190357\/Leading-Players-in-the-Antibody-Drug-Conjugate-ADC-Market-01-01-01-01-1024x542.jpg 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/01\/12190357\/Leading-Players-in-the-Antibody-Drug-Conjugate-ADC-Market-01-01-01-01-300x159.jpg 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/01\/12190357\/Leading-Players-in-the-Antibody-Drug-Conjugate-ADC-Market-01-01-01-01-768x407.jpg 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/01\/12190357\/Leading-Players-in-the-Antibody-Drug-Conjugate-ADC-Market-01-01-01-01-1536x813.jpg 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/01\/12190357\/Leading-Players-in-the-Antibody-Drug-Conjugate-ADC-Market-01-01-01-01-1568x830.jpg 1568w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/01\/12190357\/Leading-Players-in-the-Antibody-Drug-Conjugate-ADC-Market-01-01-01-01.jpg 1992w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><figcaption><strong>Global Pharma Giants in the Antibody-Drug Conjugate (ADC) Segment<\/strong><\/figcaption><\/figure>\n\n\n\n<p>Other potential Antibody-drug Conjugate therapies are owned by <strong>GlaxoSmithKline, <\/strong>which has 1 key ADC product in the pipeline. In August 2020, GSK won FDA approval for <strong>Blenrep,<\/strong> which is approved for multiple myeloma treatment for patients who have failed four previous treatments. <strong>Mersana Therapeutics <\/strong>has a lineup of 4 ADC in the pipeline. It has two antibody-drug conjugates working towards ovarian cancer and <a href=\"https:\/\/www.delveinsight.com\/report-store\/non-small-cell-lung-cancer-market\">non-small cell lung cancer treatment<\/a>. The lead candidate is <strong>upifitamab rilsodotin <\/strong>and secondary product <strong>XMT-1592, <\/strong>both target NaPi2b antigen expressed in the above-mentioned cancers.<\/p>\n\n\n\n<p>Antibody-drug Conjugate\u2019s complex design could be able to work in long-term cancer treatment. Also, it becomes challenging for such a complex drug to be recreated or copied in the form of biosimilars. The lack of biosimilars in the Antibody-drug Conjugate market will create freedom of pricing for the ADC developing pioneers. A major mix of top-notch pharmaceuticals has set their foot in the <a href=\"https:\/\/www.delveinsight.com\/report-store\/antibody-drug-conjugate-market\">Antibody-drug Conjugate treatment landscape<\/a>, which includes other names such as <strong>Abbvie, Immunogen, Sanofi, Bayer AG, Celldex Therapeutics Inc., Concortis Biotherapeutics, Seattle Genetics Inc, Synthon Holding B.V., Takeda Pharmaceutical Company Ltd., <\/strong>and several others. These companies can transform the Antibody-drug Conjugate market outlook and achieve various milestones in the coming years due to the presence of an exceptionally growing market.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>In the year 2000, the first-ever Antibody-drug Conjugate (ADC) &#8211; Mylotarg, was launched by Pfizer and was considered a miracle in cancer treatment. And it appeared like there was no looking back for these antibody-drug conjugates. But it took almost another 11 years for the next ADC to launch in the market &#8211; Adectris by [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":15359,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[78,137,159,19005,18620,19004,6733],"industry":[17225],"therapeutic_areas":[17228],"class_list":["post-15357","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-antibody-drug-conjugates","tag-cancer","tag-cervical-cancer","tag-diffuse-large-b-cell-lymphoma-2","tag-dlbcl","tag-hodgkin-lymphoma","tag-non-small-cell-lung-cancer","industry-pharmaceutical","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Insights into the Antibody-Drug Conjugate Market and Key Companies<\/title>\n<meta name=\"description\" content=\"At present, there are 11 FDA-approved Antibody-Drug Conjugate available in the oncology market and several are in various clinical stages\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/antibody-drug-conjugate-pipeline\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Insights into the Antibody-Drug Conjugate Market and Key Companies\" \/>\n<meta property=\"og:description\" content=\"At present, there are 11 FDA-approved Antibody-Drug Conjugate available in the oncology market and several are in various clinical stages\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/antibody-drug-conjugate-pipeline\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2022-01-12T13:38:43+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-01-12T14:40:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/01\/12190103\/antibody-drug-conjugate-pipeline.png\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Insights into the Antibody-Drug Conjugate Market and Key Companies","description":"At present, there are 11 FDA-approved Antibody-Drug Conjugate available in the oncology market and several are in various clinical stages","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/antibody-drug-conjugate-pipeline","og_locale":"en_US","og_type":"article","og_title":"Insights into the Antibody-Drug Conjugate Market and Key Companies","og_description":"At present, there are 11 FDA-approved Antibody-Drug Conjugate available in the oncology market and several are in various clinical stages","og_url":"https:\/\/www.delveinsight.com\/blog\/antibody-drug-conjugate-pipeline","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2022-01-12T13:38:43+00:00","article_modified_time":"2022-01-12T14:40:21+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/01\/12190103\/antibody-drug-conjugate-pipeline.png","type":"image\/png"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/antibody-drug-conjugate-pipeline","url":"https:\/\/www.delveinsight.com\/blog\/antibody-drug-conjugate-pipeline","name":"Insights into the Antibody-Drug Conjugate Market and Key Companies","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/antibody-drug-conjugate-pipeline#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/antibody-drug-conjugate-pipeline#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/01\/12190103\/antibody-drug-conjugate-pipeline.png","datePublished":"2022-01-12T13:38:43+00:00","dateModified":"2022-01-12T14:40:21+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/0d96a31a370c143ffdb481d985d7edfd"},"description":"At present, there are 11 FDA-approved Antibody-Drug Conjugate available in the oncology market and several are in various clinical stages","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/antibody-drug-conjugate-pipeline"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/antibody-drug-conjugate-pipeline#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/01\/12190103\/antibody-drug-conjugate-pipeline.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/01\/12190103\/antibody-drug-conjugate-pipeline.png","width":772,"height":482,"caption":"antibody-drug-conjugate-pipeline"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/0d96a31a370c143ffdb481d985d7edfd","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/f9314f22b8c5b61d496451e91f32488d2457ecb59283b7b2ad7e82d330b47aba?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f9314f22b8c5b61d496451e91f32488d2457ecb59283b7b2ad7e82d330b47aba?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/arawat"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/01\/12190103\/antibody-drug-conjugate-pipeline-300x187.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Antibody-Drug Conjugates<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Cervical cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">diffuse large B-cell lymphoma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">DLBCL<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Hodgkin lymphoma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Non-small cell lung cancer<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Antibody-Drug Conjugates<\/span>","<span class=\"advgb-post-tax-term\">Cancer<\/span>","<span class=\"advgb-post-tax-term\">Cervical cancer<\/span>","<span class=\"advgb-post-tax-term\">diffuse large B-cell lymphoma<\/span>","<span class=\"advgb-post-tax-term\">DLBCL<\/span>","<span class=\"advgb-post-tax-term\">Hodgkin lymphoma<\/span>","<span class=\"advgb-post-tax-term\">Non-small cell lung cancer<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 4 years ago","modified":"Updated 4 years ago"},"absolute_dates":{"created":"Posted on Jan 12, 2022","modified":"Updated on Jan 12, 2022"},"absolute_dates_time":{"created":"Posted on Jan 12, 2022 7:08 pm","modified":"Updated on Jan 12, 2022 8:10 pm"},"featured_img_caption":"antibody-drug-conjugate-pipeline","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/15357","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=15357"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/15357\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/15359"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=15357"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=15357"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=15357"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=15357"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=15357"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}